Real-World data reveals Luspatercept's impact on Lower-Risk MDS patients
NCT ID NCT06851065
First seen Feb 18, 2026 · Last updated May 07, 2026 · Updated 19 times
Summary
This study looked back at medical records of 418 adults with lower-risk myelodysplastic syndromes (MDS) who had not received prior treatment with ESAs. Researchers wanted to see how doctors actually use luspatercept and what happens to patients, including blood transfusion needs, blood count improvements, and any side effects. The goal is to better understand real-world effectiveness and treatment patterns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
RTI Health Solutions
Raleigh, North Carolina, 27709-2194, United States
Conditions
Explore the condition pages connected to this study.